Cancer News and Research

Latest Cancer News and Research

Penn Medicine tests FLASH proton therapy for cancer patients

A new form of proton therapy-designed to deliver cancer-killing radiation therapy in less than a second, through fewer total sessions, with potentially less risk of damaging side effects-is now being tested in a Phase I clinical trial at the Abramson Cancer Center of the University of Pennsylvania.

1 Sep 2026

Study reveals how melanoma weakens skin cell immune defenses

Cancers actively remodel their surrounding cells and tissues to create a microenvironment that favors their growth, survival, and spread.

1 Sep 2026

New scLS algorithm advances gene expression trajectory analysis

Single-cell RNA sequencing (scRNA-seq) is a method to measure gene expression of individual cells, allowing observation of various cellular processes, including cell differentiation, the cell cycle, and stimulus-response for each unique cell instead of averaging across millions of cells.

1 Sep 2026

Immunotherapy shows potential for treating rising gynecological tumors

Gynecological tumors, including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC), represent a significant global health burden for women.

1 Sep 2026

New method based on human blood simplifies mRNA drug development

mRNA-based drugs are emerging as the drug of the future for a wide range of diseases, but they are difficult and time-consuming to develop.

1 Sep 2026

BeOne Medicines announces voluntary agreement with U.S. Government to expand access to innovative cancer medicines

BeOne Medicines, Ltd., a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale.

1 Sep 2026

Early-onset bowel cancer shows distinct biological and clinical features

One of Australia's largest real world studies of younger adults with advanced bowel cancer has identified important differences between cancers diagnosed before and after the age of 50, which could help doctors tailor treatments for younger adults more effectively.

1 Sep 2026

Social media messages could empower parents to prevent teen vaping

Parents are an important line of defense against teen vaping, yet many lack the knowledge and tools needed to recognize vaping products, understand their risks and prevent their children from using them.

31 Aug 2026

AI tools map tumor architecture to predict treatment response

Spatial transcriptomics is a powerful tool to create a detailed map of not just how genes are expressed in a piece of tissue, but also where genetic activity takes place in different cells and locations within the tissue.

31 Aug 2026

Multimorbidity linked to shorter lifespans in aging dogs

As dogs age, many develop more than one chronic health condition. New research from the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) shows those conditions can dramatically shorten a dog's lifespan, highlighting the importance of managing multiple diseases together rather than individually.

31 Aug 2026

New ASICA app helps melanoma survivors check their skin

Researchers behind an app designed to support people after skin cancer treatment are inviting former early-stage melanoma patients to take part in its final evaluation tests.

31 Aug 2026

New dual-drug strategy blocks triple-negative breast cancer growth

Triple-negative breast cancer (TNBC) has a frustrating ability to adapt. Although this aggressive form of breast cancer can initially respond well to chemotherapy, cancer cells often find ways to survive, allowing the disease to return and become resistant to treatment.

31 Aug 2026

Routine referral of prostate cancer patients to a cardiovascular specialist fails to cut cardiac events

Men with prostate cancer have a high risk of heart disease, especially when treated with hormone therapy.

31 Aug 2026

UC San Diego researchers win DARPA award to develop improved red blood cells

Researchers at the University of California San Diego School of Medicine have been awarded a contract of up to $11.312 million from the Defense Advanced Research Projects Agency (DARPA) to pursue a high-risk, high-reward research project aimed at developing optimized red blood cells that can temporarily boost human performance and health.

31 Aug 2026

Newly discovered lung immune cells could transform future flu vaccine design

Influenza continues to cause major illness each year in the United States, leading to more than 35,000 deaths annually. Children, older adults, pregnant individuals, people with weakened immune systems, and those with chronic conditions such as heart disease, metabolic disorders, and cancer are especially vulnerable.

31 Aug 2026

Protein build-up may shape cancer drug response

The way cancer-causing proteins accumulate in tumors may influence how effectively a promising new generation of medicines can remove them, a study suggests.

31 Aug 2026

Your skin may offer clues about how many fruits and vegetables you eat

In an exploratory study of 137 Australian adults, skin yellowness measured by reflectance spectroscopy was associated with combined fruit and vegetable intake, fruit intake alone, total carotenoid intake, body fat percentage and skin color. The findings suggest skin measurements could provide an objective dietary biomarker, but the researchers caution that skin color, ethnicity and other individual characteristics may influence how the measurements are interpreted.

30 Aug 2026

Breast cancer survivors could avoid lifelong heart medication, research suggests

Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers and most won't need to continue treatment long-term, according to a study funded by the British Heart Foundation and presented at the European Society of Cardiology Congress in Munich.

30 Aug 2026

FDA approves daraxonrasib for patients with metastatic pancreatic cancer

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts of the body and continued to progress despite previous treatment.

29 Aug 2026

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

From Dana-Farber Cancer Institute, Inc. 29 Aug 2026